

Heleen H Decory

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8735915/publications.pdf>

Version: 2024-02-01

16
papers

495
citations

933264

10
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

514
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 4419-4430.	0.9	0
2	An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes. <i>Ophthalmology and Therapy</i> , 2020, 9, 159-173.	1.0	7
3	Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%. <i>PLoS ONE</i> , 2020, 15, e0237603.	1.1	8
4	Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018. <i>JAMA Ophthalmology</i> , 2020, 138, 439.	1.4	86
5	<p>Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies</p>. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1427-1438.	0.9	8
6	Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 138-145.	1.1	13
7	Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness. <i>Current Eye Research</i> , 2018, 43, 43-51.	0.7	10
8	The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 52-60.	0.6	47
9	Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. <i>PLoS ONE</i> , 2018, 13, e0205814.	1.1	35
10	Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery. <i>Clinical Ophthalmology</i> , 2015, 9, 843.	0.9	3
11	Antibiotic Resistance Among Ocular Pathogens in the United States. <i>JAMA Ophthalmology</i> , 2015, 133, 1445.	1.4	129
12	Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. <i>Clinical Ophthalmology</i> , 2013, 7, 299.	0.9	27
13	Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate. <i>International Journal of Inflammation</i> , 2012, 2012, 1-11.	0.9	71
14	Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with <i>Pseudomonas aeruginosa</i> infections. <i>Clinical Ophthalmology</i> , 2012, 6, 1987.	0.9	12
15	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. <i>Clinical Ophthalmology</i> , 2011, 5, 1359.	0.9	5
16	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. <i>Clinical Ophthalmology</i> , 2011, 5, 1369.	0.9	34